GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Shiller PE Ratio

PHAR (Pharming Group) Shiller PE Ratio : (As of Jul. 24, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharming Group Shiller PE Ratio Historical Data

The historical data trend for Pharming Group's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Shiller PE Ratio Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharming Group's Shiller PE Ratio

For the Biotechnology subindustry, Pharming Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's Shiller PE Ratio falls into.


;
;

Pharming Group Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pharming Group's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Pharming Group's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.22/133.3300*133.3300
=-0.220

Current CPI (Mar. 2025) = 133.3300.

Pharming Group Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -0.068 100.230 -0.090
201509 -0.066 100.500 -0.088
201512 -0.106 99.730 -0.142
201603 -0.091 100.310 -0.121
201606 -0.088 100.260 -0.117
201609 -0.102 100.570 -0.135
201612 -0.161 100.710 -0.213
201703 -0.128 101.440 -0.168
201706 -0.598 101.370 -0.787
201709 -0.201 102.030 -0.263
201712 -0.919 101.970 -1.202
201803 0.099 102.470 0.129
201806 0.051 103.100 0.066
201809 0.094 103.950 0.121
201812 0.191 103.970 0.245
201903 0.112 105.370 0.142
201906 0.115 105.840 0.145
201909 0.166 106.700 0.207
201912 0.216 106.800 0.270
202003 0.121 106.850 0.151
202006 0.160 107.510 0.198
202009 0.130 107.880 0.161
202012 0.110 107.850 0.136
202103 0.130 108.870 0.159
202106 0.060 109.670 0.073
202109 -0.010 110.790 -0.012
202112 0.030 114.010 0.035
202203 0.050 119.460 0.056
202206 0.220 119.050 0.246
202209 0.130 126.890 0.137
202212 -0.220 124.940 -0.235
202303 -0.190 124.720 -0.203
202306 0.020 125.830 0.021
202309 0.050 127.160 0.052
202312 -0.050 126.450 -0.053
202403 -0.190 128.580 -0.197
202406 -0.010 129.910 -0.010
202409 -0.020 131.610 -0.020
202412 0.040 131.630 0.041
202503 -0.220 133.330 -0.220

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharming Group  (NAS:PHAR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Pharming Group Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Pharming Group's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.